The pentavalent is a vaccine against Diphtheria, Pertussis, Tetanus, Hepatitis B, and Haemophilus type B influenza. A child is considered a pentavalent vaccination dropout if they have received the first dosage as advised but have not obtained the third dose. In Tanzania, the first-dose receiver of pentavalent was approximately 97 %, whereas only 89 % received a third dose. Unfortunately, no studies have been done in Tanzania to evaluate the factors at the national level that are linked with first-versus third-dose pentavalent vaccine dropout; hence, we explored these factors here for the first time. A cross-sectional survey of randomly selected households was conducted. The sample size was calculated to provide overall, age- and sex-specific coverage estimates for measles-rubella vaccine evaluation among children aged between 9 and 59 months at the national level, as explained elsewhere. The fieldwork activities were done for one month from November to December 2019 for both Zanzibar and Tanzania Mainland. A total of 4460 caregivers of children aged 12-23 months were interviewed for routine immunization services, and a total of 4403 caregivers were included in this analysis of the uptake of the pentavalent vaccine. The number of children who received the first dose of the pentavalent vaccine was 4020 (91.5 %), while the number of children who received the third dose of the pentavalent vaccine was 3915 (89.4 %). The overall pentavalent vaccination dropout rate was 2.3 %. The rate was lower in Zanzibar (0.9 %) than in the Tanzanian mainland (2.4 %). Wealth quintile, sex of caregivers, and education were factors significantly associated with the pentavalent-3 dropout rate among children aged 12-23 months in Tanzania. Our results provide strong support for further efforts to improve current vaccination coverage to optimize the use of prioritized, timely, and appropriate interventions at the regional and district levels and to improve the health education given to expectant women during their clinic visits so they may comprehend the value of routine immunization.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.vaccine.2025.126962 | DOI Listing |
J Immunol
January 2025
Center for Inflammation, Immunity and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, United States.
Current influenza vaccines are not effective in conferring protection against antigenic variants and pandemics. To improve cross-protection of influenza vaccination, we developed a 5xM2e messenger RNA (mRNA) vaccine encoding the tandem repeat conserved ectodomain (M2e) of ion channel protein M2 derived from human, swine, and avian influenza A viruses. The lipid nanoparticle (LNP)-encapsulated 5xM2e mRNA vaccine was immunogenic, eliciting high levels of M2e-specific IgG antibodies, IFN-γ+ T cells, T follicular helper cells, germinal center phenotypic B cells, and plasma cells.
View Article and Find Full Text PDFFront Allergy
February 2025
R&D Department, Fundación Inmunotek, Alcalá de Henares, Spain.
Background: Polysensitized patients require allergen immunotherapy (AIT) targeting multiple allergens. However, combining allergen extracts can lead to instability and reduced efficacy particularly due to the high proteolytic activity of house dust mite (HDM) allergens. While is known that glutaraldehyde cross-linking may reduce enzymatic activity, its ability to stabilize multi-allergen formulations and protect key allergens from degradation remains unexplored.
View Article and Find Full Text PDFSci Rep
March 2025
Department of Microbiology & One Health, ICMR-Regional Medical Research Centre (Dept. of Health Research, Ministry of Health & Family Welfare, Govt. of India), Chandrasekharpur, Bhubaneswar, 751023, India.
In a population-based survey, Hepatitis B virus (HBV) infection status, associated risk factors and vaccine coverage among the 4006 Particularly Vulnerable Tribal Groups (PVTG) participants of Odisha Tribal Family Health Survey (OTFHS) were assessed using various viral markers. All the HBsAg-positive sera were screened for viral load estimation, envelopment antigen (HBeAg) identification and liver profile parameters. The overall prevalence of HBsAg was 5.
View Article and Find Full Text PDFVaccine
March 2025
Medical Evidence, Vaccines & Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Background: Booster doses of COVID-19 vaccines are required to maintain protection against SARS-CoV-2. However, real-world evidence from South America, needed to inform optimal vaccination strategies, is lacking. Herein, we present the final analysis of REFORCO-Brazil, a large-scale assessment of relative vaccine effectiveness (rVE) of second boosters (vs first boosters) against hospitalization with COVID-19.
View Article and Find Full Text PDFProc Natl Acad Sci U S A
March 2025
Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
Pancreatic ductal adenocarcinoma (PDAC) is notoriously immune-resistant, limiting the clinical efficacy of single-agent immune modulators and thereby necessitating the exploration of multimodal immunotherapy combinations. Traditional approaches combining conventional immune checkpoint inhibitors with neoantigen vaccines have shown some promise in treating PDAC but are often compromised by intratumoral T lymphocyte exhaustion and systemic toxicity. Hence, novel approaches are needed to address these challenges.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!